Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
View Patent ↗The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.
1. A method for lowering elevated blood glucose in a patient comprising administering to said patient a therapeutically effective amount of an agent selected from the group consisting of (a) unacylated ghrelin; (b) the unacylated ghrelin of (a) having one or more conservative amino acid substitutions; and (c) pharmaceutically acceptable salts of (a) and (b).
2. The method of claim 1 , wherein the elevated blood glucose is associated with insulin resistance.
3. The method of claim 1 , wherein the elevated blood glucose is associated with insulin deficiency.
4. The method of claim 1 , wherein the agent antagonizes acylated ghrelin.
5. The method of claim 1 , wherein said agent is administered through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and inhalation.
6. The method of claim 1 , wherein said agent is administered in a dose varying from about 0.001 μg/kg to 10.0 μg/kg.
7. The method of claim 1 , wherein said agent is administered in a dose varying from about 1 μg/kg to 1 mg/kg.
8. The method of claim 1 , wherein the elevated blood glucose is associated with a postprandial insulin resistance.
9. The method of claim 1 , wherein the elevated blood glucose is associated with a body weight increase in a patient suffering from a condition selected from the group consisting of type II diabetes and syndrome X.
10. The method of claim 1 , wherein said unacylated ghrelin comprises the amino acid sequence set forth in SEQ ID NO: 1.
11. The method of claim 1 , wherein the unacylated ghrelin having one or more conservative amino acid substitutions is naturally-occurring.
12. A method for modulating and/or treating insulin resistance in a patient comprising administering to said patient a therapeutically effective amount of an agent selected from the group consisting of (a) unacylated ghrelin; (b) the unacylated ghrelin of (a) having one or more conservative amino acid substitutions; and (c) pharmaceutically acceptable salts of (a) and (b).
13. The method of claim 12 , wherein said agent is administered through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and inhalation.
14. The method of claim 12 , wherein said agent is administered in a dose varying from about 0.001 μg/kg to 10.0 μg/kg.
15. The method of claim 12 , wherein said agent is administered in a dose varying from about 1 μg/kg to 1 mg/kg.
16. The method of claim 12 , wherein said patient is in severe catabolism.
17. The method of claim 12 , wherein the patient suffers from type II diabetes.
18. The method of claim 12 , wherein the insulin resistance is associated with low growth hormone action.
19. The method of claim 12 , wherein the insulin resistance is postprandial.
20. The method of claim 12 , wherein said unacylated ghrelin comprises the amino acid sequence set forth in SEQ ID NO: 1.
21. The method of claim 12 , wherein the unacylated ghrelin having one or more conservative amino acid substitutions is naturally-occurring.